SAMANTHA JUSTICE: Open Payments
NPI 1013267152 · TISHOMINGO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 55 payments from 10 companies in 2025. Trend: 2023 $652 · 2024 $723 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $291 |
| Amgen Inc. | 5 | $77 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| IBSA Pharma Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $35 |
| PFIZER INC. | 2 | $35 |
| Novo Nordisk Inc | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
Products named: VRAYLAR, UBRELVY, QULIPTA, NEXLETOL, FARXIGA, JARDIANCE, OTEZLA, Tirosint.
Industry payments across MS — which companies pay providers there.
